InvestSMART

Botanix Pharmaceuticals Ltd (ASX:BOT)

ALERT: Price-sensitive ASX Announcement for BOT
Current share price for BOT : $0.023 0.001 (4.55%)+
Announcement
Release
7 Jul 2026 9:14AM
Price at Release
$0.022
Full Release
download
Summary
Botanix Pharmaceuticals Ltd, a dermatology company based in Philadelphia and Phoenix, announced the European Patent Office's intention to grant a patent for its proprietary applicator technology used with Sofdra topical gel, 12.45%. This gel is the first new chemical entity approved by the FDA for treating primary axillary hyperhidrosis. The patent, once formally granted, will cover the applicator's features designed for controlled administration and protection against unwanted drug contact, providing protection until May 2039. This development strengthens Botanix's intellectual property, supporting potential commercialization pathways in Europe. Dr. Howie McKibbon, Botanix's CEO, highlighted the importance of the applicator in enhancing the Sofdra product profile, which is not yet available in Europe.
Key Points
  • Botanix Pharmaceuticals Ltd receives EPO's intention to grant a patent.
  • Patent covers applicator technology for Sofdra topical gel.
  • Sofdra is approved by FDA for primary axillary hyperhidrosis.
  • Patent protection expected until May 2039.
  • Enhances Botanix's intellectual property estate.
  • Supports potential commercialization in Europe where Sofdra is unavailable.
  • CEO Dr. Howie McKibbon highlights the applicator's significance.
  • Vince Ippolito, Executive Chairman, authorized the release.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.